GRTS News and Press, Gritstone Oncology Inc. From 10/25/22

Gritstone bio ( NASDAQ: GRTS ) on Tuesday said its self-amplifying mRNA (samRNA) COVID vaccine showed tolerability and immunogenicity in two phase 1 trials. CORAL-CEPI : The study includes 340 people and is evaluating T cell-enhanced omicron- and beta-s...

Clinical-stage biotechnology company Gritstone bio ( NASDAQ: GRTS ) will sell 6.6M shares, through private investment in public equity financing, at $2.26 per share. The securities purchase agreement that the company has executed to sell also involves 13.3M pre-funded...

EMERYVILLE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that it has executed a securities purchase agreement to sell, through a private inve...

-- New data from CORAL-BOOST study demonstrate broad and durable immune response; high neutralizing antibody and T cell responses at 6 months post-boost vaccination -- -- Interim results from CORAL-CEPI show good tolerability and immunogenicity in all vaccine-naïve subjects...

-- Data to be presented from CORAL-BOOST and CORAL-CEPI trials evaluating Gritstone’s samRNA vaccine candidates against SARS-CoV-2 -- EMERYVILLE, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims t...

Summary Gritstone bio results from the phase 1/2 study, using SLATE vaccines in treating patients with KRAS mutant MSS-CRC and NSCLC, were positive with a 39% molecular response observed. Molecular response achieved in KRAS mutant NSCLC patients led to a doubling of overall surviv...

The following slide deck was published by Gritstone bio, Inc. in conjunction with this event. For further details see: Gritstone bio (GRTS) Presents at ESMO Congress 2022

Why The Stock Market Is Down Today The stock market is down today because of the latest round of August CPI data . The numbers came in higher than expected and what many hoped to be another month showing inflation was slowing became the stark reality that Fed Chairman Jerome Powell&...

Gritstone bio ( NASDAQ: GRTS ) said its SLATE vaccines (version 1 and SLATE-KRAS) showed early evidence of efficacy with a 39% molecular response rate in evaluable patients with late-line microsatellite-stable colorectal cancer (MSS-CRC) and non-small cell lung cancer (NSCLC...

-- SLATE vaccines (version 1 and SLATE-KRAS) demonstrate early evidence of efficacy with a 39% molecular response rate in evaluable patients with late-line microsatellite-stable colorectal cancer (MSS-CRC) and non-small cell lung cancer (NSCLC) -- -- Molecular response, as measu...